Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 962,192,960
  • Shares Outstanding, K 945,384
  • Annual Sales, $ 45,043 M
  • Annual Income, $ 10,590 M
  • EBIT $ 19,815 M
  • EBITDA $ 21,582 M
  • 60-Month Beta 0.43
  • Price/Sales 20.75
  • Price/Cash Flow 69.45
  • Price/Book 39.19

Options Overview Details

View History
  • Implied Volatility 36.82% ( +1.05%)
  • Historical Volatility 27.74%
  • IV Percentile 57%
  • IV Rank 29.56%
  • IV High 64.53% on 04/07/25
  • IV Low 25.20% on 02/06/25
  • Put/Call Vol Ratio 0.25
  • Today's Volume 57,163
  • Volume Avg (30-Day) 63,225
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 489,130
  • Open Int (30-Day) 429,189

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 7.30
  • Number of Estimates 7
  • High Estimate 8.78
  • Low Estimate 6.83
  • Prior Year 5.32
  • Growth Rate Est. (year over year) +37.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
783.85 +31.11%
on 10/17/25
1,032.79 -0.49%
on 11/13/25
+208.31 (+25.42%)
since 10/13/25
3-Month
655.10 +56.88%
on 08/14/25
1,032.79 -0.49%
on 11/13/25
+367.22 (+55.60%)
since 08/13/25
52-Week
623.78 +64.76%
on 08/08/25
1,032.79 -0.49%
on 11/13/25
+215.90 (+26.60%)
since 11/13/24

Most Recent Stories

More News
1 Unpopular Stock That Deserves a Second Chance and 2 We Question

1 Unpopular Stock That Deserves a Second Chance and 2 We Question

LLY : 1,028.83 (+1.09%)
CATY : 47.30 (+0.94%)
THR : 35.05 (-1.49%)
Stocks Finish Sharply Higher on Plans to Reopen the US Government

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +1.54%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.81%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +2.20%. December E-mini...

GOOGL : 280.33 (-2.23%)
AAPL : 273.53 (+0.02%)
ADI : 237.83 (-1.50%)
CLS : 293.83 (-12.18%)
ELV : 330.91 (+1.00%)
TSLA : 403.24 (-6.35%)
WDC : 160.38 (-3.45%)
AMD : 253.01 (-2.27%)
UPS : 96.87 (+0.72%)
SPY : 675.78 (-1.11%)
META : 610.03 (+0.17%)
UHS : 227.60 (-0.36%)
Why Eli Lilly (LLY) Stock Is Trading Up Today

Why Eli Lilly (LLY) Stock Is Trading Up Today

LLY : 1,028.83 (+1.09%)
Stocks Supported by Hopes the US Government Will Soon Reopen

The S&P 500 Index ($SPX ) (SPY ) today is up +1.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.55%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.81%. December E-mini S&P futures (ESZ25...

AMAT : 223.50 (-3.13%)
GOOGL : 280.33 (-2.23%)
AAPL : 273.53 (+0.02%)
B : 37.10 (-0.62%)
GFI : 41.90 (-2.24%)
CLS : 293.83 (-12.18%)
$IUXX : 25,083.63 (-1.70%)
ELV : 330.91 (+1.00%)
ZNZ25 : 112-255 (-0.18%)
MSFT : 509.03 (-0.41%)
MNDY : 161.43 (+1.46%)
TSLA : 403.24 (-6.35%)
Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'

New innovative campaign weaves science and storytelling to help reframe obesity as a chronic disease

LLY : 1,028.83 (+1.09%)
2 Growth Stocks with All-Star Potential and 1 We Question

2 Growth Stocks with All-Star Potential and 1 We Question

USPH : 71.44 (-1.50%)
DDOG : 188.01 (-1.51%)
LLY : 1,028.83 (+1.09%)
U.S. Strikes Landmark Drug Pricing Deals With Eli Lilly and Novo Nordisk

The Trump administration announced new agreements with Eli Lilly ($LLY) and Novo Nordisk ($NVO) to lower prices for obesity and primary care drugs, while securing major U.S. investments and a temporary...

NVO : 49.76 (-0.99%)
LLY : 1,028.83 (+1.09%)
Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

INDIANAPOLIS , Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles...

LLY : 1,028.83 (+1.09%)
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans

 Medicare beneficiaries with obesity or overweight will have access to Zepbound and orforglipron, if approved, at $50 a month 

LLY : 1,028.83 (+1.09%)
Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight

Based on these trial results, Lilly will begin enrolling Phase 3 clinical studies for the treatment of obesity next month

LLY : 1,028.83 (+1.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 1,062.42
2nd Resistance Point 1,042.42
1st Resistance Point 1,030.10
Last Price 1,028.83
1st Support Level 997.78
2nd Support Level 977.78
3rd Support Level 965.46

See More

52-Week High 1,032.79
Last Price 1,028.49
Fibonacci 61.8% 876.55
Fibonacci 50% 828.29
Fibonacci 38.2% 780.02
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar